Download biomedica product list
Endostatin is an independent risk factor of graft loss after kidney transplant
Researchers from Germany have identified the endothelial basement membrane biomarker endostatin that can better predict the risk of graft loss in kidney transplant recipients (KTRs) in a prospective observational cohort study with 574 maintenance KTRs (median follow-up 48 months).
“.. increased serum endostatin concentrations at baseline are independently associated with the risk of graft loss in prevalent KTRs. Its association with graft loss seems to be even stronger as compared to the established classical risk factors for graft loss: decreased GFR and increased urinary protein excretion.“
Endostatin is an independent risk factor of graft loss after kidney transplant. Chu C et al., Am J Nephrol. 2020 Apr 22;51(5):373-380.
Biomedica’s FULLY VALIDATED human and mouse/rat Endostatin ELISAs
Human Endostatin can easily be measured by ELISA assay
√ for serum, plasma, and urine samples
√ SIMPLE analysis – results in 4.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA
Also available:
Mouse/Rat Endostatin ELISA – only 5µl sample volume required